TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18189207

Group type: EXPERIMENTAL
Intervention: Social support variables for women
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Social support variables for men
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Existing social support
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Non‐using sexual partners for men
Number of subjects: 435
Study: 16324861

Group type: EXPERIMENTAL
Intervention: Combination of morphine 0.1 mg kg(‐1) with ketamine 0.15 mg kg(‐1) (group KM)
Number of subjects: 69
Study: 12067327

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 17
Study: 10340240

Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 65
Study: 8572782

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Modified and Conventional ultrafiltration)
Number of subjects: 50
Study: 1936509

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6790966

Group type: EXPERIMENTAL
Intervention: Heparin-Dihydergot 2500
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional low dose heparin regimen
Number of subjects: 350
Study: 30098049

Group type: EXPERIMENTAL
Intervention: Anticholinergic exposure (defined by four methods for each of four anticholinergic scales: Anticholinergic Drug Scale, Anticholinergic Cognitive Burden, Anticholinergic Risk Scale, the Durán list)
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Non-anticholinergic agent users
Number of subjects: 1396
Study: 27428644

Group type: EXPERIMENTAL
Intervention: Video feedback (VI) group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 59
Study: 25639827

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cord milking
Number of subjects: 58
Study: 25022109

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zusanli (ST 36) and Neiguan (PC 6) with additional points based on syndrome differentiation, stimulated with disperse-dense wave at 2 Hz/100 Hz, once a day for 4 sessions (5 days each session)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Domperidone, 10 mg orally, three times a day for 4 sessions (5 days each session)
Number of subjects: 70
Study: 23063071

Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb) plus erlotinib (150 mg oral daily)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Erlotinib alone (150 mg oral daily)
Number of subjects: 490
Study: 19039022

Group type: EXPERIMENTAL
Intervention: Cpn10 (5 mg or 10 mg weekly for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17329479

Group type: EXPERIMENTAL
Intervention: 20 mg of memantine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 40 mg of memantine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15249354

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Probability function based on GLUMEAN and GLUSD
Number of subjects: 195
Study: 11114445

Group type: EXPERIMENTAL
Intervention: Braced condition
Number of subjects: 4

Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 4
Study: 10450451

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of one-fifth dose of purified Vero-cell rabies vaccine (PVRV) with routine DTP-IPV vaccines (2, 3, 4 months)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of 2 doses of PVRV (2, 4 months) with routine DTP-IPV vaccines (2, 3, 4 months)
Number of subjects: 240
Study: 7846538

Group type: EXPERIMENTAL
Intervention: Single-agent ifosfamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard combination chemotherapy (cyclophosphamide/doxorubicin/vincristine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide combined with carboplatin and etoposide
Number of subjects: 0
Study: 2129649

Group type: EXPERIMENTAL
Intervention: Colestipol 2.5 g b.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colestipol 5 g b.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colestipol 7.5 g b.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo b.d.
Number of subjects: 40
Study: 6171687

Group type: EXPERIMENTAL
Intervention: Trimazosin (300 mg single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31263524

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) training, 8 sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 27997327

Group type: EXPERIMENTAL
Intervention: Behavioral activation and therapeutic exposure (BA-TE)
Number of subjects: 45
Study: 23710900

Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bone drilling
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 18
Study: 22289389

Group type: EXPERIMENTAL
Intervention: Microwave energy device treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 120
Study: 20305369

Group type: EXPERIMENTAL
Intervention: Physical training program (aerobic, muscle strength, balance)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nutritional intervention program (individually targeted advice and group sessions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of physical training and nutritional intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 18298870

Group type: EXPERIMENTAL
Intervention: 500 ml semi-skimmed milk (1200 mg calcium)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No milk supplement
Number of subjects: 30
Study: 16117978

Group type: EXPERIMENTAL
Intervention: FF‐muG 130 mg with food
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: FF‐muG 130 mg without food
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 14685054

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once daily
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Atazanavir 600 mg once daily
Number of subjects: 467

Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg twice a day
Number of subjects: 467
Study: 10863994

Group type: EXPERIMENTAL
Intervention: Low-salt diet (LS; sodium chloride intake <5 g per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Normal-salt diet (NS; normal food ad libitum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-salt diet (HS; normal food plus NaCl 100 mg/kg per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute oral water load of 1500 ml
Number of subjects: 10
Study: 8667868

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Non-surgery (control)
Number of subjects: 1599
Study: 1625504

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. for four weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for four weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omeprazole-treated patients re-examined 10 days after drug withdrawal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omeprazole-treated patients re-examined 15 days after drug withdrawal
Number of subjects: 24
Study: 6613908

Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (100 g or more at least twice a week for 3 months)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Little or no fatty fish (for another 3 months)
Number of subjects: 118
Study: 3960476

Group type: EXPERIMENTAL
Intervention: The Meditec OPL3 mode‐locked Nd:YAG laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: The LASAG Microruptor 2 Q‐switched Nd:YAG laser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical Indomethacin and topical steroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with topical steroids
Number of subjects: 0
Study: 31663173

Group type: EXPERIMENTAL
Intervention: Mid-follicular phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mid-luteal phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inactive-pill phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active-pill phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mid-follicular phase (non-oral contraceptive users)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mid-luteal phase (non-oral contraceptive users)
Number of subjects: 30
Study: 29912858

Group type: EXPERIMENTAL
Intervention: Caffeine (∼280 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9
Study: 27343175

Group type: EXPERIMENTAL
Intervention: Dipyridamole treatment for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal coronary arteries)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) measurements
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional Doppler parameters
Number of subjects: 40
Study: 24365194

Group type: EXPERIMENTAL
Intervention: Vitamin C infusion (3-g infusion within 6 hours before PCI)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 532
Study: 23260537

Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tongue appliance
Number of subjects: 45
Study: 20889601

Group type: EXPERIMENTAL
Intervention: ADA plus MTX
Number of subjects: 799

Group type: COMPARATOR
Intervention: ADA
Number of subjects: 799

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 799
Study: 19192867

Group type: EXPERIMENTAL
Intervention: Monetary reinforcement accrued with consecutive instances of abstinence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Money deducted for failure to abstain
Number of subjects: 0
Study: 15668427

Group type: EXPERIMENTAL
Intervention: 100 mg testosterone enanthate plus daily oral placebo pill (T group, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg testosterone enanthate plus 1 mg daily of anastrozole (AT group, n = 19)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injection and placebo pill (placebo group, n = 21)
Number of subjects: 60
Study: 14566150

Group type: EXPERIMENTAL
Intervention: Square plate (30 x 30 mm) under the left lateral plantar eminence
Number of subjects: 8

Group type: COMPARATOR
Intervention: Square plate (3 mm or 6 mm thickness) under the left medial plantar eminence
Number of subjects: 8

Group type: COMPARATOR
Intervention: Square plate (3 mm or 6 mm thickness) under the left forefoot sole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rectangular plate (120 x 30 mm) under the left metatarsal heads (3 mm or 6 mm thickness)
Number of subjects: 8
Study: 10950767

Group type: EXPERIMENTAL
Intervention: Rtv/Sqv
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Rtv
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Idr
Number of subjects: 318

Group type: COMPARATOR
Intervention: All arms
Number of subjects: 318
Study: 9004341

Group type: EXPERIMENTAL
Intervention: Broad eligibility criteria for clozapine
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Stringent eligibility criteria for clozapine
Number of subjects: 505
Study: 1477491

Group type: EXPERIMENTAL
Intervention: zuclopenthixol dihydrochloride tablets (10 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 52
Study: 30704571

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery combined with optimal medical therapy (OMT)
Number of subjects: 4953

Group type: EXPERIMENTAL
Intervention: CABG + OMT
Number of subjects: 4953

Group type: COMPARATOR
Intervention: CKD (mild and moderate to severe)
Number of subjects: 4953
Study: 29769828

Group type: EXPERIMENTAL
Intervention: 7 min RW
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 3 min RW
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 27614374

Group type: EXPERIMENTAL
Intervention: Bougie-guided single lung intubation
Number of subjects: 45
Study: 24465443

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg daily with lopinavir/ritonavir
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg three times per week with lopinavir/ritonavir
Number of subjects: 33

Group type: COMPARATOR
Intervention: Rifabutin 300 mg alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both dosing regimens of rifabutin
Number of subjects: 33
Study: 23131372

Group type: EXPERIMENTAL
Intervention: Acupressure intervention on Shenmen (He7), He Gu (Li4), and Sanyingjao (sp6) points for 4 weeks alongside routine care
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 48
Study: 20573975

Group type: EXPERIMENTAL
Intervention: Hypergravity condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic phases under hypergravity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control test with increased object mass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control test with change in movement kinematics
Number of subjects: 20
Study: 17696277

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily (n = 34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No prednisolone (n = 33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Prednisolone treated for at least 4 years
Number of subjects: 67
Study: 16181540

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract injection (GB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study: 12057714

Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg/d for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 40
Study: 10816058

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard CPB circuits
Number of subjects: 19
Study: 8655904

Group type: EXPERIMENTAL
Intervention: 4-day food record (4DFR)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Telephone recall (TR)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (no counseling about fat intake)
Number of subjects: 290
Study: 1297896

Group type: EXPERIMENTAL
Intervention: New chewable, buffered ASA tablet formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain ASA tablet formulation
Number of subjects: 12
Study: 6384203

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 40
Study: 30664617

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Bupropion-escitalopram combination
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Venlafaxine-mirtazapine combination
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Metabolite-based models
Number of subjects: 159
Study: 29191745

Group type: EXPERIMENTAL
Intervention: Traffic Light Labels
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Health Star Rating labels
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Nutrition Information Panels (control)
Number of subjects: 1255
Study: 26318671

Group type: EXPERIMENTAL
Intervention: mHealth (text messaging-based) HIV prevention program
Number of subjects: 302
Study: 24193291

Group type: EXPERIMENTAL
Intervention: Irsogladine maleate (IM) 4 mg/body/day for two years
Number of subjects: 305

Group type: COMPARATOR
Intervention: Uracil-tegafur (250 mg/m2/day) for two years (Control)
Number of subjects: 305
Study: 21367595

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg daily for 12 months
Number of subjects: 24
Study: 18330806

Group type: EXPERIMENTAL
Intervention: Insole with toe separator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 30
Study: 16534529

Group type: EXPERIMENTAL
Intervention: Fat Booters Incorporated (FBI)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Individualised Dietetic Treatment (IDT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Information Booklet Only (BO)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both intervention groups (FBI and IDT)
Number of subjects: 176
Study: 12927929

Group type: EXPERIMENTAL
Intervention: Twice daily interferon (IFN)-beta (3 MU bid)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Once daily interferon (IFN)-beta (6 MU qd)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 10773790

Group type: EXPERIMENTAL
Intervention: Fructose 1,6-diphosphate (FDP) administration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9326983

Group type: EXPERIMENTAL
Intervention: Cardiac pacing at 30 beats/min above sinus rhythm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous sodium nitroprusside
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intracoronary nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intracoronary felodipine
Number of subjects: 12
Study: 8462430

Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 92
Study: 3512747

Group type: EXPERIMENTAL
Intervention: Naproxen 5 mg/kg twice daily for eight weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29582137

Group type: EXPERIMENTAL
Intervention: Hymenoptera
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Odonata
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Diptera
Number of subjects: 3
Study: 27829454

Group type: EXPERIMENTAL
Intervention: 4-week dose reduction group (N = 125)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: 26-week dose reduction group (N = 120)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (N = 129)
Number of subjects: 374
Study: 24088010

Group type: EXPERIMENTAL
Intervention: Horse riding therapy (six 30-minute sessions)
Number of subjects: 40
Study: 22086491

Group type: EXPERIMENTAL
Intervention: Progressive home-based strengthening exercise program (PHSEP) for 8 weeks in addition to weekly institutional exercise therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group continued weekly institutional exercise sessions
Number of subjects: 36
Study: 20737957

Group type: EXPERIMENTAL
Intervention: Systemic medical treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined therapy of medicine and adenoidectomy and/or tonsillectomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Systemic medical treatment and endoscopic sinus surgery
Number of subjects: 88
Study: 18382340

Group type: EXPERIMENTAL
Intervention: Office-based vision therapy/orthoptics
Number of subjects: 95

Group type: COMPARATOR
Intervention: Office-based placebo vision therapy/orthoptics
Number of subjects: 95
Study: 17119057

Group type: EXPERIMENTAL
Intervention: High heme diet (beef, blood sausage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heme supplemented diet (120 g/d red meat, baseline diet supplemented with heme iron)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High heme diet (rats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (chicken, baseline diet)
Number of subjects: 0
Study: 12393528

Group type: EXPERIMENTAL
Intervention: Iron chelation treatment
Number of subjects: 39
Study: 10994157

Group type: EXPERIMENTAL
Intervention: Oral enzyme combination product (OE; Phlogenzym(®), containing trypsin, bromelain and rutin)
Number of subjects: 2139

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAID)
Number of subjects: 2139

Group type: EXPERIMENTAL
Intervention: Oral enzyme combination product (OE)
Number of subjects: 2139
Study: 8791954

Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg b.d. + placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg b.d. + omeprazole 40 mg b.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.d. + placebo
Number of subjects: 24
Study: 7890900

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b (3 million units, subcutaneously, 3 times a week for 3 months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 33
Study: 3063044

Group type: EXPERIMENTAL
Intervention: Propofol 2.2 mg/kg i.v.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Thiopentone 4.0 mg/kg i.v.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Methohexitone 2.0 mg/kg i.v.
Number of subjects: 75
Study: 30170904

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen treatment for 2 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: No oxygen treatment for 2 weeks
Number of subjects: 84
Study: 27075216

Group type: EXPERIMENTAL
Intervention: Proactive treatment group (intermittent preventive application of topical corticosteroid for 1 year)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reactive treatment group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proactive treatment group
Number of subjects: 30
Study: 24152600

Group type: EXPERIMENTAL
Intervention: Assistive Technology and Telecare (ATT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Equivalent community services (Control)
Number of subjects: 500
Study: 21855126

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma symptoms requiring albuterol (NASRAs)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma symptoms requiring albuterol (NASRAs) during exacerbation periods
Number of subjects: 285
Study: 20008205

Group type: EXPERIMENTAL
Intervention: Primary prophylaxis for thrombotic complications
Number of subjects: 1
Study: 17898099

Group type: EXPERIMENTAL
Intervention: Statins treatment with varying HDL cholesterol levels
Number of subjects: 9770

Group type: EXPERIMENTAL
Intervention: Statins treatment with HDL cholesterol in the highest quintile
Number of subjects: 9770